Thach-Giao Truong, MD, discusses the ImmunoCobiVem trial of early switch from targeted therapy to immunotherapy in advanced BRAF V600–positive melanoma.
Thach-Giao Truong, MD
Advertisement
Articles by Thach-Giao Truong, MD
Thach-Giao Truong, MD, discusses the ImmunoCobiVem trial investigating the switch from targeted therapy to immunotherapy in advanced BRAF V600+ melanoma.
Experts from across oncology specialties discuss the abstracts and presentations they are most looking forward to seeing at the 2024 ESMO Congress.
Advertisement
Latest Updated Articles
Oncology Experts Preview Top Abstracts From the 2024 ESMO CongressSeptember 11th 2024
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Bioequivalent Olaparib Across Previously Approved Cancer Indications
2
Alpha DaRT Plus Pembrolizumab Yields 100% ORR in Elderly Recurrent or Metastatic HNSCC
3
Longer-Term Data Help Shape TKI Selection in ROS1+ and ALK+ NSCLC
4
Experts Revisit the Most Notable Data in GU Oncology From ASCO 2026
5